Board of Directors


Chairman of the Board

Cavan Redmond joined the Board of Directors in September of 2015.  Mr. Redmond is a seasoned healthcare strategist, who has held a number of global leadership positions.  He currently is a partner at Zarsy, LLC.  His global leadership roles include: CEO of WebMD Health Corp., where he oversaw cost rationalizations and streamlined operations to position the company for growth; Senior Vice President and Group President, Pfizer Diversified Businesses.  The Diversified Business included Animal Health, Consumer Healthcare, Capsugel and Nutrition. While at Pfizer he also became the head of Corporate Strategy. While at Wyeth he was the first EVP and General Manager Wyeth Biopharma and President of Wyeth Consumer Healthcare.  He is currently a member of  the Board of Directors for the Arthritis Foundation, where he has served since 2014.   Mr. Redmond holds a MAS degree from Johns Hopkins University and a  BA from the University of Maryland at College Park. He was a 2012 recipient of The Johns Hopkins University Distinguished Alumnus Award.




William Annett joined OncoCyte as Chief Executive Officer in June 2015. Mr. Annett’s diagnostics industry experience includes his service as CEO of BioFX Laboratories, Inc., which created innovative products in the in vitro diagnostics field and was successfully sold to a large life sciences company. He founded and led Corra Life Sciences, a prenatal diagnostics company, which worked with a consortium of universities to develop blood tests for the major diseases of pregnancy. Early in his career, Mr. Annett also founded a consumer products company, which he led for six years as CEO. During his tenure, the company became publicly traded on NASDAQ and was then acquired.

At Genentech, Mr. Annett led the Commercial Strategy group and managed large operational projects with several hundred team members. He also directed the Project Finance function for R&D, which supported all development pipeline products with more than 200 clinical trials. Most recently, Mr. Annett was a Managing Director at Accenture where he founded, built, and headed Accenture’s West Coast Life Sciences practice with sales, marketing, and delivery responsibilities for the entire territory. His clients included most of the major biotech and pharmaceutical companies in the western United States.

Mr. Annett holds an MBA from the Harvard Business School.



Mr. Andrews is the Founder and Principal of The Bethesda Group, a company focused on helping organizations in the molecular diagnostics and genomics industries. Prior to founding The Bethesda Group, he served as President of the Genetic Sciences Division at Thermo Fisher Scientific following a merger with Life Technologies. During the merger, he oversaw the integration of Ion Torrent with the traditional genetic platform and content initiatives within Life Technologies to form a $2 billion division. Previously, Mr. Andrews served as Chief Executive Officer and Segment Leader of GE Molecular Diagnostics at Clarient Inc. from 2004 until 2012 and oversaw the transition into GE Healthcare and expansion of GE’s presence in oncology. While at Clarient, he transformed ChromaVision Medical Systems from a device manufacturer to a comprehensive cancer diagnostics company. Mr. Andrews currently serves on the Board of Directors of Insight Genetics, Orion Healthcare, and Oxford Immunotec.



Andy Arno was appointed as a member of the Board of Directors in June 2015. He is currently Vice Chairman of “The Special Equities Group” at Chardan Capital Markets, LLC, a privately held investment banking firm. He was previously Managing Director of Emerging Growth Equities, an investment bank, and Vice President of Sabr, Inc., as well as President of LOMUSA Limited, an investment banking firm. From 2009 to 2012, Andy served as Vice Chairman and Chief Marketing Officer of Unterberg Capital, LLC, an investment advisory firm that he co-founded. He also served as Vice Chairman and Head of Equity Capital Markets of Merriman Capital LLC, an investment banking firm, and served on the board of its parent company, Merriman Holdings, Inc. Mr. Arno currently serves on the Boards of Asterias Biotherapeutics, Comhear, and Smith Micro Software, Inc. He is a graduate of George Washington University.



Alfred D. Kingsley joined the Board of Directors in 2009 and was previously Chairman of the Board. Mr. Kingsley has been general partner of Greenway Partners, L.P., a private investment firm, and President of Greenbelt Corp., a business consulting firm, since 1993. Greenbelt Corp. served as our financial advisor from 1998 until June 30, 2009. Mr. Kingsley was Senior Vice-President of Icahn and Company and its affiliated entities for more than 25 years. Mr. Kingsley holds a BS degree in economics from the Wharton School of the University of Pennsylvania, and a J.D. degree and LLM in taxation from New York University Law School.



Andrew J. Last joined the Board of Directors in December 2015. In January of 2018, Dr. Last was appointed as Chief Commercial Officer at Berkeley Lights. Previously, he served as Chief Operating Officer of Intrexon Corporation. From 2010 to 2016, Dr. Last was Executive Vice President and Chief Operating Officer of Affymetrix. Before joining Affymetrix, Dr. Last served as Vice President, Global and Strategic Marketing of BD Biosciences and as General Manager of Pharmingen from 2004 to 2010. From 2002 to 2004, Dr. Last held management positions at Applied Biosystems, Inc., including as Vice President and General Manager from 2003-2004 and Vice President of Marking 2002-2003. Earlier in his career, he served in a variety of management positions at other companies, including Incyte Genomics and Monsanto. Dr. Last holds Ph. D. and MS degrees with specialization in Agrochemical Chemicals and Bio-Aeronautics, respectively, from Cranfield University, and a BS degree in Biological Sciences from the University of Leicester in the United Kingdom.



Adi Mohanty joined the Board of Directors in April 2015. Mr. Mohanty currently has served as BioTime’s, Chief Operating Officer since December 2014 and Co-Chief Executive Officer since October 2015. He was formerly with Shire plc, a biotechnology company focused on research, development and commercialization of novel biological products for rare diseases, where he served in a number of executive positions, including as President/Head Regenerative Medicine from 2013 to 2014, as Senior Vice President, Business and Technical Operations from 2012 to 2013, and as Global Franchise Head MPS from 2010 to 2012. Mr. Mohanty served as Vice President at Transkaryotic Therapies from 2002 to 2005 when it was acquired by Shire. Before joining Transkaryotic Therapies, Mr. Mohanty held a number of management positions in the Bioscience Division of Baxter Healthcare Corporation. Mr. Mohanty received an MBA degree from Saint Mary’s College and has an MS and BS in Chemical Engineering.